These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22834666)

  • 1. Platelet count alterations associated with escitalopram, venlafaxine and bupropion in depressive patients.
    Song HR; Jung YE; Wang HR; Woo YS; Jun TY; Bahk WM
    Psychiatry Clin Neurosci; 2012 Aug; 66(5):457-9. PubMed ID: 22834666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
    Montgomery SA; Huusom AK; Bothmer J
    Neuropsychobiology; 2004; 50(1):57-64. PubMed ID: 15179022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of cardiorespiratory coordination in young women with recurrent major depressive disorder treated with escitalopram or venlafaxine.
    Chang JS; Ha K; Yoon IY; Yoo CS; Yi SH; Her JY; Ha TH; Park T
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):136-42. PubMed ID: 22699029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA
    J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of venlafaxine with bupropion: risks associated with a triple monoamine reuptake inhibition approach to partially responsive depression.
    Andrade C
    J Clin Psychiatry; 2013 Feb; 74(2):e119-21. PubMed ID: 23473356
    [No Abstract]   [Full Text] [Related]  

  • 9. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
    Gaynes BN; Dusetzina SB; Ellis AR; Hansen RA; Farley JF; Miller WC; Stürmer T
    J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant.
    Katz AJ; Dusetzina SB; Farley JF; Ellis AR; Gaynes BN; Castillo WC; Stürmer T; Hansen RA
    Pharmacotherapy; 2012 Mar; 32(3):234-43. PubMed ID: 22392456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring.
    Gründer G; Wetzel H; Schlösser R; Benkert O
    Pharmacopsychiatry; 1996 Mar; 29(2):72-8. PubMed ID: 8741025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
    Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
    J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Severe forms of depression: the efficacy of escitalopram].
    Spadone C
    Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?
    Perlis RH; Uher R; Perroud N; Fava M
    J Clin Psychiatry; 2012 Nov; 73(11):1439-42. PubMed ID: 23059018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram.
    Allard P; Gram L; Timdahl K; Behnke K; Hanson M; Søgaard J
    Int J Geriatr Psychiatry; 2004 Dec; 19(12):1123-30. PubMed ID: 15526307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness.
    Hannan N; Hamzah Z; Akinpeloye HO; Meagher D
    J Psychopharmacol; 2007 Mar; 21(2):161-4. PubMed ID: 17329295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram induced thrombocytopenia reversed after shifting to bupropion in a depressive patient.
    Chu CW; Chao PC; Chang HA; Liu YW; Chang TC; Lin PY; Chang CC
    Aust N Z J Psychiatry; 2017 Oct; 51(10):1055-1056. PubMed ID: 28349712
    [No Abstract]   [Full Text] [Related]  

  • 20. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.